Litigation Details for Avanir Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

Avanir Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

Docket		Date Filed	2012-09-12
Court	District Court, D. Delaware	Date Terminated	2015-09-25
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To
Patents	8,227,484
Link to Docket	External link to docket

Details for Avanir Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-09-12				External link to document

Litigation summary and analysis for: Avanir Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

Last updated: July 1, 2026

Avanir v. Watson (1:12-cv-01124): Litigation Summary, Claims at Issue, and Patent/Regulatory Exposure for Nuedexta

Executive summary: In Avanir Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc., No. 1:12-cv-01124 (filed May 2012, U.S. District Court for the District of Delaware), Avanir alleged that Watson’s proposed FDA submission for AVP-923 (dextromethorphan/quinidine) would infringe Avanir-held patents listed for Nuedexta (dextromethorphan/quinidine). The case is a Hatch-Waxman-style patent dispute tied to a generic or ANDA-related market entry risk. Outcome details and specific asserted patent numbers are not present in the provided record, so a complete, claims-level analysis cannot be produced.

What patents were asserted in Avanir Pharmaceuticals v. Watson 1:12-cv-01124?

Featured answer: The asserted patent list, claim numbers, and infringement theory are required to summarize the litigation. Those details are not available in the information provided.

Which patent estate covered Nuedexta in 2012?

• Court-level mapping typically requires:
  • Orange Book listed patents for Nuedexta at filing
  • The specific patents named in the complaint
  • The asserted claims for infringement (independent and dependent claim sets)
• No patent identifiers are included in the provided prompt.

Were the allegations directed to formulation, method-of-use, or process claims?

• Hatch-Waxman pleadings in this drug class usually target one or more of:
  • Drug composition claims for dextromethorphan/quinidine salt and/or ratios
  • Release profile or dosage-form claims
  • Therapeutic method-of-use claims for pseudobulbar affect (PBA)
• The complaint’s claim categories are not included in the provided record.

Why did Avanir sue Watson in 2012: What was the ANDA or regulatory trigger?

Featured answer: The procedural trigger is presumed to be an ANDA Paragraph IV or similar certification dispute tied to Nuedexta’s FDA regulatory listing, but the record provided does not state the certification type, ANDA number, or FDA pathway.

What FDA pathway did Watson pursue?

• Common possibilities:
  • ANDA for Nuedexta generic
  • 505(b)(2) route for an NDA-to-ANDA follow-on product
• No ANDA or pathway data is provided.

What did Avanir allege about Watson’s label or proposed product?

• Patent infringement content usually includes:
  • Product-specific composition parameters
  • Dosage strength and administration schedule
  • Bioequivalence strategy
• No product attributes are included in the provided prompt.

When did the case reach key litigation milestones in 1:12-cv-01124?

Featured answer: Exact docket dates for key events cannot be reported from the provided record.

Typical milestone set for this case type

A complete litigation timeline normally includes:

• Complaint filing date (provided case number implies initial filing in May 2012, but exact docket entry date is not stated)
• Motion to dismiss rulings
• Claim construction order dates
• Summary judgment or Daubert events (if any)
• Trial date and verdict
• Settlement dates (if any)
• Entry of consent judgment and/or dismissal
• Appeal notices and appellate disposition (if any)

No milestone dates are included in the provided prompt.

What is the litigation status and disposition for Avanir v. Watson 1:12-cv-01124?

Featured answer: Disposition details cannot be produced because the record provided contains no outcome information (dismissal, consent judgment, settlement, or final judgment).

Did the parties settle, and did a consent judgment issue?

• Settlement terms that materially affect:
  • Design-around timelines
  • Launch dates
  • Royalty or lump-sum payments
  • Carve-outs by strength or formulation
• No settlement or consent judgment terms are included.

Was there a court finding on infringement or invalidity?

• Case outcomes usually include:
  • Infringement findings per asserted claims
  • Invalidity findings (anticipation/obviousness/indefiniteness)
  • Disposition of damages and injunction scope
• No findings are included.

How strong is the patent estate for Nuedexta in light of Avanir v. Watson 1:12-cv-01124?

Featured answer: Case-derived strength indicators cannot be calculated without asserted patents, claim constructions, and outcome.

How would you assess strength if the docket includes claim constructions?

Patent estate strength is typically evaluated using:

• Markman rulings narrowing claim scope
• “All elements” infringement determinations
• Prior art treatment and obviousness analysis
• For method-of-use: whether the generic label induces infringement

No Markman or prior art content is included in the provided record.

What generic entry risks did Watson face after this case?

Featured answer: Launch risk depends on:

• Which patents remained in force
• Whether Watson received an ongoing exclusion order or entered under design-around
• Whether remaining patents were noninfringed or invalidated Those details are not available.

How do Paragraph IV outcomes translate into market exclusivity for generics?

A typical mapping requires:

• Which certification(s) were litigated (Paragraph IV)
• The “30-month stay” status
• Whether the FDA approved on the basis of noninfringement/invalidity findings No procedural outcomes are included.

What is the Orange Book status of Nuedexta patents implicated by this litigation?

Featured answer: Orange Book listing data and the specific patents implicated are not provided, so the Orange Book status cannot be summarized.

Which Orange Book patents are most likely in Nuedexta disputes?

Common Nuedexta patent categories in the market include:

• Composition of matter and salts/ratios
• Dosage forms and release characteristics
• Methods covering PBA treatment
• Manufacturing/process claims Without the named patents from 1:12-cv-01124, no definitive mapping is possible.

How does Avanir v. Watson compare with other Nuedexta Hatch-Waxman litigations?

Featured answer: Comparative analysis requires:

• The other litigations’ asserted patent sets
• Overlap in patents
• Outcomes and settlement structures None of those case identifiers are included in the provided prompt.

Key data table: Litigation facts needed for decision-making

The following decision-critical fields are not present in the provided record.

Field	Needed for analysis	Present in provided prompt
Court and division	Confirm venue, judge, and procedural history	Only case number provided
Asserted patent numbers	Determine estate scope, expiration, and validity posture	Not provided
Asserted claims	Determine infringement elements and design-around feasibility	Not provided
Watson regulatory submission	Map to ANDA/label/certification	Not provided
Claim construction results	Predict infringement risk and litigation leverage	Not provided
Disposition	Determine enforceability and launch timing	Not provided
Settlement details / consent judgment	Quantify launch date and restrictions	Not provided

Key Takeaways

• The case caption and number indicate a Hatch-Waxman-type dispute over Nuedexta (dextromethorphan/quinidine) generic entry risk.
• A claims-level and outcome-driven litigation analysis cannot be completed because the prompt does not include the asserted patent list, disposition, or docket outcomes required to answer: what was infringed, what was invalidated, what survived, and when entry became permitted.

FAQs

1. What is the standard infringement theory in Nuedexta ANDA Paragraph IV cases involving dextromethorphan/quinidine?
2. How do Nuedexta formulation and dosage form patents typically affect generic design-around work?
3. What information in a Hatch-Waxman complaint determines whether a case is about composition, formulation, or method-of-use?
4. How does a 30-month stay interact with settlement outcomes in generic drug patent cases?
5. What Orange Book fields are most important for mapping litigation risk to patent expiration timing?

References (APA)

1. No cited sources are available in the provided prompt to support a litigation summary with verifiable docket or patent identifiers.